UroGen Pharma Ltd. develops and commercializes therapies for urothelial and specialty cancers, with recurring updates centered on approved mitomycin products and its RTGel® reverse-thermal hydrogel platform. Company announcements commonly address JELMYTO for low-grade upper tract urothelial cancer and ZUSDURI for adults with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer, including product revenue, reimbursement coding, physician education and real-world treatment experience.
UroGen news also covers clinical data publications, pipeline programs such as UGN-103 and UGN-501, research and development spending, debt financing, employee equity inducement grants and investor-conference participation. The company’s updates connect commercial execution with sustained-release local therapy designed to increase urinary tract tissue exposure to medication.
UroGen Pharma (Nasdaq: URGN) will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 1:50 PM ET in Boston, MA. The presentation includes a formal talk and 1x1 investor meetings.
Webcast access is available on the company website under Events & Presentations, with a replay available for about 30 days.
UroGen Pharma (Nasdaq: URGN) will report fourth quarter and full-year 2025 financial results on Monday, March 2, 2026, before the market opens. A live audio webcast and conference call will follow at 10:00 AM Eastern Time.
According to the company, the live public webcast will be accessible via its investor relations website, with a replay available on the site for approximately 30 days after the call.
UroGen Pharma (Nasdaq: URGN) will present at the Guggenheim Securities Emerging Outlook: Biotech Summit on February 12, 2026 at 2:30 PM ET in New York.
Format includes a fireside chat and 1x1 investor meetings. A live webcast will be available on UroGen’s Events & Presentations page, with a replay accessible for approximately 90 days.
UroGen (Nasdaq: URGN) announced that the permanent HCPCS Level II J Code J9282 for ZUSDURI (mitomycin) intravesical solution became effective January 1, 2026. The code was assigned by the Centers for Medicare & Medicaid Services and is expected to streamline billing and reimbursement in hospital outpatient and physician office settings, reducing administrative delays and improving timely patient access to ZUSDURI. ZUSDURI is described as the first and only FDA‑approved therapy for adults with recurrent low‑grade intermediate‑risk non–muscle invasive bladder cancer (LG‑IR‑NMIBC). Use of J9282 for eligible Medicare claims is available as of January 1, 2026, subject to individual payer coverage policies.
UroGen Pharma (Nasdaq: URGN) announced on December 5, 2025 inducement grants of restricted stock units (RSUs) to 14 new employees under its 2019 Inducement Plan in connection with their employment.
Up to 32,500 ordinary shares are issuable upon vesting. The RSUs vest equally over three years (one-third each year on the anniversary of the vesting date), subject to continued service and the RSU agreement terms. Grants were made as inducements in accordance with Nasdaq Listing Rule 5635(c)(4). New hires will support commercialization of Jelmyto (mitomycin) for pyelocalyceal solution and ZUSDURI (mitomycin) for intravesical solution and UroGen’s pipeline development.
UroGen Pharma (Nasdaq: URGN) will present at the Piper Sandler 37th Annual Healthcare Conference taking place December 2-4, 2025. The company is scheduled for a fireside chat on December 2, 2025 at 1:00 PM ET in New York, NY.
Investors can watch a live webcast and access a replay on UroGen’s Investor Relations website; the replay will be available for approximately 90 days.
UroGen (Nasdaq: URGN) reported Q3 2025 results as its newly launched ZUSDURI gains early commercial traction and development milestones advance.
Key points: ZUSDURI net product revenue of $1.8M in Q3 with an October preliminary demand estimate of $4.5M; JELMYTO net product revenue of $25.7M in Q3 (+~13% underlying YoY demand growth); cash and marketable securities of $127.4M as of Sept 30, 2025; three-month complete response rate for UGN-103 of 77.8% (95% CI 68.3%–85.5%); FDA agreed to an NDA submission plan for UGN-103 and UGN-103 NDA anticipated in H2 2026 with potential approval in 2027; ZUSDURI assigned permanent J-code J9282 effective Jan 1, 2026.
UroGen (Nasdaq: URGN) reported a 77.8% three-month complete response (CR) rate (95% CI, 68.3%–85.5%) from the ongoing Phase 3 UTOPIA trial of UGN-103 in recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).
The result is consistent with a 79.6% three-month CR observed with ZUSDURI in ENVISION. The FDA agreed that CR and durability results from UTOPIA can support a New Drug Application (NDA) for UGN-103, and the company plans to prepare an NDA submission in 2026. UroGen also holds two U.S. patents covering UGN-103 that expire in December 2041.
UroGen Pharma (Nasdaq: URGN) will present at the Guggenheim Securities Healthcare Innovation Conference in Boston on November 11, 2025 at 10:30 AM ET. The company plans a presentation plus one-on-one investor meetings during the November 10–12, 2025 conference. Webcast and replay access will be available on UroGen’s investor relations website, with the replay online for approximately 90 days. The presentation focuses on recent corporate developments and investor engagement opportunities.
UroGen Pharma (Nasdaq: URGN) will report third quarter 2025 financial results on Thursday, November 6, 2025 prior to market open. A live audio webcast and conference call will follow at 10:00 AM Eastern Time. Investors can access the live webcast and a replay on UroGen’s Investor Relations website; the replay will be available for approximately 30 days. The announcement covers the timing and access details for the Q3 2025 earnings release and related investor call.